Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect

Yoen Ju Son, Jin Sung Jang, Yong Woo Cho, Hesson Chung, Rang Won Park, Ick Chan Kwon, In-San Kim, Jae Yong Park, Sang Bong Seo, Chong Rae Park, Seo Young Jeong

Research output: Contribution to journalArticle

243 Citations (Scopus)

Abstract

An in vivo tumor targeting test of glycol-chitosan nanoaggregates was carried out with FITC-conjugated glycol-chitosan nanoaggregates (FTC-GC) and the doxorubicin conjugated glycol-chitosan (GC-DOX). To investigate its biodistribution in tumor-bearing rats, glycol-chitosan was labeled with fluorescein isothiocyanate (FITC), which formed nanoaggregates with a diameter of about 250 nm in aqueous media. GC-DOX nanoaggregates containing acid-sensitive spacers were prepared. The GC-DOX formed micelle-like nanoaggregates spontaneously in aqueous media. GC-DOX nanoaggregates had a narrow and unimodal size distribution, and its hydrodynamic diameter measured by dynamic light scattering ranged from 250 to 300 nm. A loading content of doxorubicin into GC-DOX nanoaggregates as high as 38%, with 97% loading efficiency, could be obtained using a physical entrapment method. A tumor-bearing animal model was developed by inoculating tumor cells into the back of a rat. The FTC-GC nanoaggregates were injected into the tail vein of tumor-bearing rats and their tissue distribution was examined. The FTC-GC nanoaggregates were distributed mainly in kidney, tumor and the liver and were scarcely observed in other tissues. They were maintained at a high level for 8 days and their distribution in tumor tissues increased gradually. This suggests that chitosan nanoaggregates accumulate passively in the tumor tissue due to the enhanced permeability and retention (EPR) effect. Doxorubicin loaded GC-DOX nanoaggregates (DOX/GC-DOX) were injected into the tail vein of tumor-bearing rats and their anti-tumor effect was examined. Tumor growth was suppressed over 10 days.

Original languageEnglish
Pages (from-to)135-145
Number of pages11
JournalJournal of Controlled Release
Volume91
Issue number1-2
DOIs
Publication statusPublished - 2003 Aug 28
Externally publishedYes

Fingerprint

Doxorubicin
Permeability
Neoplasms
Fluorescein-5-isothiocyanate
Fluorescein
Tail
Veins
glycol-chitosan
Chitosan
Micelles
Tissue Distribution
Hydrodynamics
Animal Models
Kidney
Acids
Liver
Growth

Keywords

  • Doxorubicin
  • Glycol-chitosan
  • Nanoaggregates
  • Targeted delivery
  • Tumor

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Son, Y. J., Jang, J. S., Cho, Y. W., Chung, H., Park, R. W., Kwon, I. C., ... Jeong, S. Y. (2003). Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. Journal of Controlled Release, 91(1-2), 135-145. https://doi.org/10.1016/S0168-3659(03)00231-1

Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. / Son, Yoen Ju; Jang, Jin Sung; Cho, Yong Woo; Chung, Hesson; Park, Rang Won; Kwon, Ick Chan; Kim, In-San; Park, Jae Yong; Seo, Sang Bong; Park, Chong Rae; Jeong, Seo Young.

In: Journal of Controlled Release, Vol. 91, No. 1-2, 28.08.2003, p. 135-145.

Research output: Contribution to journalArticle

Son, YJ, Jang, JS, Cho, YW, Chung, H, Park, RW, Kwon, IC, Kim, I-S, Park, JY, Seo, SB, Park, CR & Jeong, SY 2003, 'Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect', Journal of Controlled Release, vol. 91, no. 1-2, pp. 135-145. https://doi.org/10.1016/S0168-3659(03)00231-1
Son, Yoen Ju ; Jang, Jin Sung ; Cho, Yong Woo ; Chung, Hesson ; Park, Rang Won ; Kwon, Ick Chan ; Kim, In-San ; Park, Jae Yong ; Seo, Sang Bong ; Park, Chong Rae ; Jeong, Seo Young. / Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. In: Journal of Controlled Release. 2003 ; Vol. 91, No. 1-2. pp. 135-145.
@article{14f7100e4759468f88872720f9a48d53,
title = "Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect",
abstract = "An in vivo tumor targeting test of glycol-chitosan nanoaggregates was carried out with FITC-conjugated glycol-chitosan nanoaggregates (FTC-GC) and the doxorubicin conjugated glycol-chitosan (GC-DOX). To investigate its biodistribution in tumor-bearing rats, glycol-chitosan was labeled with fluorescein isothiocyanate (FITC), which formed nanoaggregates with a diameter of about 250 nm in aqueous media. GC-DOX nanoaggregates containing acid-sensitive spacers were prepared. The GC-DOX formed micelle-like nanoaggregates spontaneously in aqueous media. GC-DOX nanoaggregates had a narrow and unimodal size distribution, and its hydrodynamic diameter measured by dynamic light scattering ranged from 250 to 300 nm. A loading content of doxorubicin into GC-DOX nanoaggregates as high as 38{\%}, with 97{\%} loading efficiency, could be obtained using a physical entrapment method. A tumor-bearing animal model was developed by inoculating tumor cells into the back of a rat. The FTC-GC nanoaggregates were injected into the tail vein of tumor-bearing rats and their tissue distribution was examined. The FTC-GC nanoaggregates were distributed mainly in kidney, tumor and the liver and were scarcely observed in other tissues. They were maintained at a high level for 8 days and their distribution in tumor tissues increased gradually. This suggests that chitosan nanoaggregates accumulate passively in the tumor tissue due to the enhanced permeability and retention (EPR) effect. Doxorubicin loaded GC-DOX nanoaggregates (DOX/GC-DOX) were injected into the tail vein of tumor-bearing rats and their anti-tumor effect was examined. Tumor growth was suppressed over 10 days.",
keywords = "Doxorubicin, Glycol-chitosan, Nanoaggregates, Targeted delivery, Tumor",
author = "Son, {Yoen Ju} and Jang, {Jin Sung} and Cho, {Yong Woo} and Hesson Chung and Park, {Rang Won} and Kwon, {Ick Chan} and In-San Kim and Park, {Jae Yong} and Seo, {Sang Bong} and Park, {Chong Rae} and Jeong, {Seo Young}",
year = "2003",
month = "8",
day = "28",
doi = "10.1016/S0168-3659(03)00231-1",
language = "English",
volume = "91",
pages = "135--145",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect

AU - Son, Yoen Ju

AU - Jang, Jin Sung

AU - Cho, Yong Woo

AU - Chung, Hesson

AU - Park, Rang Won

AU - Kwon, Ick Chan

AU - Kim, In-San

AU - Park, Jae Yong

AU - Seo, Sang Bong

AU - Park, Chong Rae

AU - Jeong, Seo Young

PY - 2003/8/28

Y1 - 2003/8/28

N2 - An in vivo tumor targeting test of glycol-chitosan nanoaggregates was carried out with FITC-conjugated glycol-chitosan nanoaggregates (FTC-GC) and the doxorubicin conjugated glycol-chitosan (GC-DOX). To investigate its biodistribution in tumor-bearing rats, glycol-chitosan was labeled with fluorescein isothiocyanate (FITC), which formed nanoaggregates with a diameter of about 250 nm in aqueous media. GC-DOX nanoaggregates containing acid-sensitive spacers were prepared. The GC-DOX formed micelle-like nanoaggregates spontaneously in aqueous media. GC-DOX nanoaggregates had a narrow and unimodal size distribution, and its hydrodynamic diameter measured by dynamic light scattering ranged from 250 to 300 nm. A loading content of doxorubicin into GC-DOX nanoaggregates as high as 38%, with 97% loading efficiency, could be obtained using a physical entrapment method. A tumor-bearing animal model was developed by inoculating tumor cells into the back of a rat. The FTC-GC nanoaggregates were injected into the tail vein of tumor-bearing rats and their tissue distribution was examined. The FTC-GC nanoaggregates were distributed mainly in kidney, tumor and the liver and were scarcely observed in other tissues. They were maintained at a high level for 8 days and their distribution in tumor tissues increased gradually. This suggests that chitosan nanoaggregates accumulate passively in the tumor tissue due to the enhanced permeability and retention (EPR) effect. Doxorubicin loaded GC-DOX nanoaggregates (DOX/GC-DOX) were injected into the tail vein of tumor-bearing rats and their anti-tumor effect was examined. Tumor growth was suppressed over 10 days.

AB - An in vivo tumor targeting test of glycol-chitosan nanoaggregates was carried out with FITC-conjugated glycol-chitosan nanoaggregates (FTC-GC) and the doxorubicin conjugated glycol-chitosan (GC-DOX). To investigate its biodistribution in tumor-bearing rats, glycol-chitosan was labeled with fluorescein isothiocyanate (FITC), which formed nanoaggregates with a diameter of about 250 nm in aqueous media. GC-DOX nanoaggregates containing acid-sensitive spacers were prepared. The GC-DOX formed micelle-like nanoaggregates spontaneously in aqueous media. GC-DOX nanoaggregates had a narrow and unimodal size distribution, and its hydrodynamic diameter measured by dynamic light scattering ranged from 250 to 300 nm. A loading content of doxorubicin into GC-DOX nanoaggregates as high as 38%, with 97% loading efficiency, could be obtained using a physical entrapment method. A tumor-bearing animal model was developed by inoculating tumor cells into the back of a rat. The FTC-GC nanoaggregates were injected into the tail vein of tumor-bearing rats and their tissue distribution was examined. The FTC-GC nanoaggregates were distributed mainly in kidney, tumor and the liver and were scarcely observed in other tissues. They were maintained at a high level for 8 days and their distribution in tumor tissues increased gradually. This suggests that chitosan nanoaggregates accumulate passively in the tumor tissue due to the enhanced permeability and retention (EPR) effect. Doxorubicin loaded GC-DOX nanoaggregates (DOX/GC-DOX) were injected into the tail vein of tumor-bearing rats and their anti-tumor effect was examined. Tumor growth was suppressed over 10 days.

KW - Doxorubicin

KW - Glycol-chitosan

KW - Nanoaggregates

KW - Targeted delivery

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=0141955912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141955912&partnerID=8YFLogxK

U2 - 10.1016/S0168-3659(03)00231-1

DO - 10.1016/S0168-3659(03)00231-1

M3 - Article

VL - 91

SP - 135

EP - 145

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1-2

ER -